0.520
-0.03 (-5.11%)
| Previous Close | 0.548 |
| Open | 0.588 |
| Volume | 982,263 |
| Avg. Volume (3M) | 486,011 |
| Market Cap | 9,089,600 |
| Price / Earnings (TTM) | 0.018 |
| Price / Sales | 0.800 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Operating Margin (TTM) | -490.52% |
| Diluted EPS (TTM) | 29.70 |
| Quarterly Revenue Growth (YOY) | -0.60% |
| Current Ratio (MRQ) | 0.600 |
| Operating Cash Flow (TTM) | -43.73 M |
| Levered Free Cash Flow (TTM) | -31.85 M |
| Return on Assets (TTM) | -90.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | T2 Biosystems, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.33 |
|
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company’s products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 4.45% |
| % Held by Institutions | 74.65% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |